PTC Therapeutics Company Profile (NASDAQ:PTCT)

About PTC Therapeutics

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTCT
  • CUSIP:
Key Metrics:
  • Previous Close: $13.31
  • 50 Day Moving Average: $13.65
  • 200 Day Moving Average: $10.86
  • 52-Week Range: $4.03 - $16.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.83
  • P/E Growth: 0.32
  • Market Cap: $446.54M
  • Outstanding Shares: 34,165,000
  • Beta: 1.38
  • Net Margins: -236.68%
  • Return on Equity: -90.33%
  • Return on Assets: -50.69%
  • Debt-to-Equity Ratio: 0.69%
  • Current Ratio: 5.74%
  • Quick Ratio: 5.74%
Additional Links:
Companies Related to PTC Therapeutics:

Analyst Ratings

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $34.00 (160.14% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
DateFirmActionRatingPrice TargetDetails
2/16/2017Credit Suisse GroupReiterated RatingPositiveView Rating Details
1/10/2017Jefferies Group LLCReiterated RatingHold$12.00View Rating Details
1/2/2017RBC Capital MarketsSet Price TargetHold$13.00View Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 -> $7.00View Rating Details
11/11/2016Royal Bank of CanadaLower Price TargetSector Perform$13.00View Rating Details
11/11/2016Citigroup Inc.UpgradeNeutral -> Buy$7.00 -> $15.00View Rating Details
11/4/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingHold$15.00View Rating Details
10/3/2016Bank of America CorpReiterated RatingHold$15.00View Rating Details
4/17/2016Oppenheimer Holdings, Inc.Reiterated RatingBuy$39.00View Rating Details
3/1/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $100.00View Rating Details
10/16/2015Roth CapitalReiterated RatingHold$63.00View Rating Details
6/17/2015Deutsche Bank AGReiterated RatingBuy$115.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for PTC Therapeutics (NASDAQ:PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)ViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
Current Year EPS Consensus Estimate: $-4.40 EPS
Next Year EPS Consensus Estimate: $-3.41 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.52)($1.00)($1.28)
Q2 20163($1.48)($0.90)($1.28)
Q3 20163($1.37)($0.90)($1.16)
Q4 20163($1.16)($1.00)($1.10)
Q1 20171($0.70)($0.70)($0.70)
Q2 20171($0.38)($0.38)($0.38)
Q3 20171($0.89)($0.89)($0.89)
Q4 20171($0.88)($0.88)($0.88)
(Data provided by Zacks Investment Research)


Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 83.66%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
News IconFiscal Year Earnings Estimate on PTC Therapeutics, Inc.(PTCT) - Money Flow Index & Trends (NASDAQ:PTCT) - February 24 at 8:18 AM logoPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire (press release) (NASDAQ:PTCT) - February 22 at 9:24 AM
News IconAnalysts Peer Into Their Crystal Balls For PTC Therapeutics, Inc. (NASDAQ:PTCT): Where Is It headed? - Winfield Review (NASDAQ:PTCT) - February 21 at 5:31 PM
News IconStock Price of PTC Therapeutics, Inc. (PTCT) Increases 10.28 ... - Highland Mirror (NASDAQ:PTCT) - February 21 at 5:31 PM
News IconEarnings Analysis & Update for PTC Therapeutics, Inc. (NASDAQ:PTCT)? - Aiken Advocate (NASDAQ:PTCT) - February 20 at 6:35 PM
News IconPending Cystic Fibrosis Trial Data, PTC Therapeutics (PTCT) is Poised to Break Out - Economic Calendar (NASDAQ:PTCT) - February 18 at 6:29 PM logoCredit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100 (NASDAQ:PTCT) - February 16 at 6:59 PM logoIs the Options Market Predicting a Spike in PTC Therapeutics (PTCT) Stock? (NASDAQ:PTCT) - February 13 at 9:03 AM
News IconMarket Focus: Checking Up on Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - Benton Bulletin (NASDAQ:PTCT) - February 11 at 2:38 AM
News IconNoteworthy Friday Option Activity: PTCT, UVV, SREV (NASDAQ:PTCT) - February 10 at 9:38 PM logoPTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy (NASDAQ:PTCT) - February 8 at 9:27 PM logoPTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : February 1, 2017 (NASDAQ:PTCT) - February 1 at 10:08 PM
News IconStock Vacillating as Volatility Hits a High Point For PTC Therapeutics, Inc. (NASDAQ:PTCT) - Wall Street Beacon (NASDAQ:PTCT) - January 31 at 9:15 PM
News IconQuarterly EPS Of PTC Therapeutics, Inc. (NASDAQ:PTCT) Set At $-0.88 - Stock Observer (NASDAQ:PTCT) - January 31 at 9:15 PM logoPTC Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTCT-US : January 31, 2017 (NASDAQ:PTCT) - January 31 at 9:15 PM
News IconTechnical Study: Following Indicators for Ptc Therapeutics Inc. (PTCT) - Springdale Times (NASDAQ:PTCT) - January 31 at 1:03 AM logoNotable Friday Option Activity: PTCT, GD, LULU (NASDAQ:PTCT) - January 28 at 5:50 AM
News IconErratic Volume Takes A Hold of This Stock: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Wall Street Beacon (NASDAQ:PTCT) - January 25 at 1:12 AM
News IconStock Perspective: PTC Therapeutics, Inc. (NASDAQ:PTCT) Company Earnings Watch - Aiken Advocate (NASDAQ:PTCT) - January 24 at 8:26 AM
News IconPriming The Pump: Stock Volatility Spotted in PTC Therapeutics, Inc. (NASDAQ:PTCT) - Wall Street Beacon (NASDAQ:PTCT) - January 24 at 8:26 AM logoIs the Options Market Predicting a Spike in PTC Therapeutics Stock? (NASDAQ:PTCT) - January 23 at 9:19 AM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Bearish Target At $20 - Stock Observer (NASDAQ:PTCT) - January 22 at 5:11 AM
News IconRSI Review on Shares of Ptc Therapeutics Inc. (PTCT) - Sherwood Daily (NASDAQ:PTCT) - January 20 at 8:31 PM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Quarterly EPS Set At $-0.88 - Stock Observer (NASDAQ:PTCT) - January 17 at 7:44 PM
News IconStock Edging Lower Out Of The Gate: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Wall Street Beacon (NASDAQ:PTCT) - January 12 at 8:00 PM
News IconWill The Needle Move For PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PTCT) - January 12 at 8:00 PM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) hit its 52 Week low of $4.03 on Nov 3, 2016 - The Newburgh Press (NASDAQ:PTCT) - January 12 at 1:03 AM
News IconStock Reaching Most Volatile List Today: PTC Therapeutics, Inc. (NASDAQ:PTCT) - Wall Street Beacon (NASDAQ:PTCT) - January 12 at 1:03 AM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Jumped 25% After The Buy Alert In 4-Week (NASDAQ:PTCT) - January 11 at 8:01 PM logo11:10 am PTC Therapeutics extends recent strength to 10-month high following presentation at JPM Healthcare Conference (NASDAQ:PTCT) - January 11 at 8:01 PM
News IconPTC Therapeutics, Inc. (NASDAQ:PTCT) Quarterly EPS Set At ... - Stock Observer (NASDAQ:PTCT) - January 10 at 8:35 PM logoSarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears (NASDAQ:PTCT) - January 10 at 8:35 PM logoPTC THERAPEUTICS, INC. (NASDAQ:PTCT) Files An 8-K Results ... - Market Exclusive (NASDAQ:PTCT) - January 10 at 1:03 AM logoPTC Therapeutics (PTCT) Says EC Ratifies Positive CHMP Opinion ... - (NASDAQ:PTCT) - January 10 at 1:03 AM logoPTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global … (NASDAQ:PTCT) - January 9 at 8:01 PM logoPTC Therapeutics (PTCT) Says EC Ratifies Positive CHMP Opinion for Renewal of Translarna MAA in nmDMD (NASDAQ:PTCT) - January 9 at 8:01 PM logoPTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna™ and Advance its Innovative Pipeline (NASDAQ:PTCT) - January 9 at 8:01 PM logoPTC THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F (NASDAQ:PTCT) - January 9 at 8:01 PM logoEuropean Commission Ratifies Positive CHMP Opinion for the Renewal of Translarna™ Marketing Authorization for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (NASDAQ:PTCT) - January 9 at 8:01 PM logoInsider Trading Activity PTC Therapeutics, Inc. (NASDAQ:PTCT) – EVP Sold 78 shares of Stock (NASDAQ:PTCT) - January 8 at 7:03 PM logoPTC Therapeutics (PTCT) RG7916 Granted FDA Orphan Drug Designation (NASDAQ:PTCT) - January 6 at 8:05 PM logo8:02 am PTC Therapeutics confirms orphan designation of RG7916 for the treatment of patients with Spinal Muscular Atrophy (NASDAQ:PTCT) - January 6 at 8:05 PM logoRG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy (NASDAQ:PTCT) - January 6 at 8:05 PM logoPTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients - PR Newswire (press release) (NASDAQ:PTCT) - January 5 at 3:26 PM logoPTC Therapeutics to Present 2017 Corporate Update at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:PTCT) - January 4 at 12:06 AM
News IconBearish Target Of PTC Therapeutics, Inc. (NASDAQ:PTCT) At $20 - Stock Observer (NASDAQ:PTCT) - December 31 at 7:13 PM
News IconAre Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock? - Yahoo Sports (NASDAQ:PTCT) - December 31 at 12:44 AM logoAre Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock? - Nasdaq (NASDAQ:PTCT) - December 30 at 12:22 AM logoAre Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock? (NASDAQ:PTCT) - December 29 at 8:59 AM
News IconCommit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options (NASDAQ:PTCT) - December 22 at 7:43 PM


What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Where is PTC Therapeutics' stock going? Where will PTC Therapeutics' stock price be in 2017?

11 analysts have issued twelve-month price targets for PTC Therapeutics' shares. Their forecasts range from $7.00 to $120.00. On average, they expect PTC Therapeutics' stock price to reach $34.00 in the next twelve months.

When will PTC Therapeutics announce their earnings?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:

  • Jefferies Group LLC analysts commented, "PTCT reported ~$81M Translarna net sales in 2016 (higher vs. our est of $75M) and guided $105-125M for 2017 sales. The topline data for Translarna Ph3 study in CF continues to be expected in late-1Q17 and the company plans to file NDA in DMD over protest in the US. Additional pipeline in SMA and cancer are progressing on-track." (1/10/2017)

  • According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (12/9/2016)

Who owns PTC Therapeutics stock?

PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (4.01%), RTW Investments LP (2.92%), Bogle Investment Management L P DE (2.21%), FMR LLC (2.14%), State Street Corp (1.74%) and Numeric Investors LLC (1.66%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, David P Southwell, Mark Elliott Boulding, Mark Rothera, Michael L Kranda, Neil Gregory Almstead, Richard Aldrich, Robert J Spiegel, Shane William Charles Kovacs and Stuart Walter Peltz.

Who sold PTC Therapeutics stock? Who is selling PTC Therapeutics stock?

PTC Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Pinnacle Associates Ltd., Commerzbank Aktiengesellschaft FI and Dimensional Fund Advisors LP.

Who bought PTC Therapeutics stock? Who is buying PTC Therapeutics stock?

PTC Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Numeric Investors LLC, FMR LLC, Sicart Associates LLC, Orbimed Advisors LLC, Frontier Capital Management Co. LLC, Oxford Asset Management and A.R.T. Advisors LLC.

How do I buy PTC Therapeutics stock?

Shares of PTC Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PTC Therapeutics stock cost?

One share of PTC Therapeutics stock can currently be purchased for approximately $13.07.

PTC Therapeutics (NASDAQ:PTCT) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Earnings History Chart

Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Dividend History Chart

Dividend Payments by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Last Updated on 2/24/2017 by Staff